

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on April 16, 2007.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121
Examining Group 1617
Patent Application
Docket No. UF-389
Serial No. 10/700,156

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jennifer M. Kim
Art Unit : 1617
Applicants : Nathan Andrew Shapira, Giselle D. Mann, April M. Annis, Toby Doris Goldsmith
Serial No. : 10/700,156
Filed : November 3, 2003
Conf. No. : 3799
For : Methods to Prevent or Ameliorate Medication-, Procedure- or Stress-Induced Cognitive and Speech Dysfunction and Methods to Optimize Cognitive and Speech Functioning

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated March 16, 2007 in the above-identified patent application, Applicants hereby elect, for purposes of examination in the subject application, the species of atomoxetine.